Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/ovid-cuts-its-losses-on-controversial-angelman-syndrome-drug-making-its-crushing-development-halt-permanent/

Max Gelman ENDPTS
20 Apr 2021

http://www.xconomy.com/new-york/2015/03/25/ex-teva-ceo-levin-is-back-with-startup-aimed-at-rare-neuro-disorders/

Ben Fidler XCONOMY
27 Mar 2015